Neuroprotection of acute ischemic stroke: Where are we?

Neuroscientist

Volumn 5, Issue 6, 1999, Pages 392-401

  Fisher, Marc ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Ischemic stroke; Neuroprotection; Pathophysiology; Treatment

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; ALBUMINOID; APTIGANEL; BASIC FIBROBLAST GROWTH FACTOR; CITICOLINE; CLOMETHIAZOLE; DEXTRORPHAN; FOSPHENYTOIN SODIUM; GAVESTINEL; LAMOTRIGINE; LANICEMINE; LUBELUZOLE; MONOCLONAL ANTIBODY; N TERT BUTYL ALPHA PHENYLNITRONE; NIMODIPINE; SIPATRIGINE; TIRILAZAD; TRIFLUOPERAZINE; [1 [(1 FORMYL 2 PHENYLETHYL)CARBAMOYL] 2 METHYLPROPYL]CARBAMIC ACID BENZYL ESTER;

ARTICLE; CALCIUM TRANSPORT; CEREBROVASCULAR ACCIDENT; DOSE RESPONSE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPOTENSION; NERVE INJURY; NEUROPROTECTION; REPERFUSION INJURY; TREATMENT PLANNING; VOMITING;

EID: 0032748815     PISSN: 10738584     EISSN: None     Source Type: Journal    
DOI: 10.1177/107385849900500614     Document Type: Article

References (77)

1. The National Institute of Neurological Disorders and Stroke rt-PA Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
2. Kristian T, Siesjo BK. Calcium in ischemic cell death. Stroke 1998;29:705-18.
3. Fisher M. Characterizing the target of acute stroke therapy. Stroke 1997;28:866-72.
4. Heiss WD, Graf R, Lottgen J, Ohta K, Fujita T, Wagner R, et al. Repeat positron emission tomographic studies in transient middle cerebral artery occlusion in cats: residual perfusion and efficacy of postischemic reperfusion. J Cereb Blood Flow Metab 1997;17: 388-400.
5. Ringelstein EB, Biniek R, Weiller C, Ammeling B, Nolte PN, Thron A. Type and extent of hemispheric brain infarctions and clinical outcome in early and delayed middle cerebral artery recanalization. Neurology 1992;42:289-98.
6. Baron JC, von Kumar R, del Zoppo GJ. Treatment of acute ischemic stroke: Challenging the concept of a rigid and universal time window. Stroke 1995;26:2219-21.
7. Fisher M, Garcia JH. Evolving stroke and the ischemic penumbra. Neurology 1996;47:684-8.
8. Steiner T, Hacke W. Combination therapy with neuroprotectants and thrombolytics in acute ischemic stroke. Eur Neurol 1998;40: 1-8.
9. Meldrum B. Protection against ischemic neuronal damage by drugs acting against excitatory neurotransmission. Cerebrovasc Brain Metab Rev 1990;2:27-57.
10. Choi DW, Lobner D, Dugan LL. Glutamate receptor-mediated neuronal death in the ischemic brain. In: Hsu C, editor. Ischemic stroke: from basic mechanisms to new drug development. Basel: Karger; 1998. p. 2-13.
11. Davalos A, Castillo J, Serena J, Noya M. Duration of glutamate release after acute ischemic stroke. Stroke 1997;28:708-10.
12. Huie RE, Padmaja S. The reaction of NO with superoxide. Free Radic Res Commun 1993;18:195-9.
13. Tettenborn D, Fierus M. Clinical aspects of nimodipine treatment in brain ischemia. Drugs Dev 1993;2:473-82.
14. Mohr J, Orgogozo JM, Harrison MJG. Meta-analysis of oral nimodipine trials in acute ischemic stroke. Cerebrovasc Dis 1994; 4:197-203.
15. Wahlgren NG, MacMahon DG, DeKeyser J, Indredvik B, Ryman T for the INWEST Study Group. Intravenous nimodipine west europe stroke trial of nimodipine in the treatment of acute ischemic stroke. Cerebrovasc Dis 1994;4:204-10.
16. Fisher M, Takano K. The penumbra, therapeutic time window and acute ischemic stroke. Baillieres Clin Neurol 1995;4:279-94.
17. Muir KW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke 1994;25:1755-9.
18. Edwards K, and the CNS 1102-008 Study Group. Cerestat (aptiganel hydrochloride) in the treatment of acute ischemic stroke. Neurology 1996;48(suppl 1):A424.
19. Izumi Y, Roussel S, Pinard E. Seylaz J. Reduction of infarct volume by magnesium after middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 1991;11:1025-30.
20. Muir KW, Lees KR. Dose optimization of intravenous magnesium sulfate after acute stroke. Stroke 1998;29:918-23.
21. Cregan EF, Peeling J, Corbett D, Buchan AM, Saunders J, Auer RN, et al. {S-alpha-phenyl-2-pyridine-ethanamine dihydrochloride} a low affinity uncompetitive n-methyl-d-aspartatic acid antagonist is effective in rodent models of global and focal ischemia. J Pharmacol Exp Ther 1997;283:1412-24.
22. Brady EM, Wells DS, Kierstead AE, Mueller AL, Newman MK, Sanguinetti EL, et al. Ascending dose safety and pharmacokinetic study of NPS 1506, a novel NMDA antagonist, in normal male volunteers [abstract]. Neurology 1998;50(suppl 4):A346.
23. GAIN Investigators. Phase 2 studies of the glycine antagonist, GV150526, in acute stroke [abstract]. Stroke 1998;29:304.
24. Onal MZ, Fisher M. Acute stroke therapy: a clinical overview. Eur Neurol 1997;38:141-54.
25. Muir KW, Lees KR, Hamilton SJC, George CF, Hobbiger SF, Lunnon MW. A randomized, double-blind, placebo controlled ascending dose tolerance study of 619C89 in acute stroke. Ann N Y Acad Sci 1995;765:328-9.
26. Gribkoff VK, Starrett JE, Dworetzky SI. The pharmacology and molecular biology of large-conductance calcium-activated (BK) potassium channels. Adv Pharmacol 1997;17:319-47.
27. Samdani AF, Dawson TM, Dawson VL. Nitric oxide synthase in models of focal ischemia. Stroke 1997;28:1283-8.
28. Bartus RT. The calpain hypothesis of neurodegeneration: evidence for a common cytotoxic pathway. THE NEUROSCIENTIST 1997;3:314-27.
29. Chan PH. Role of oxidants in ischemic brain damage. Stroke 1996;27:1124-9.
30. Mori E, Ember J, Copeland BR, Thomas WS, Koveil JA, del Zoppo GJ. Effect of tirilizad mesylate on middle cerebral artery occlusion/reperfusion in nonhuman primates. Cerebrovasc Dis 1995;5:342-9.
31. The RANTTAS Investigators. A randomized trial of tirilizad mesylate in patients with acute ischemic stroke (RANTTAS). Stroke 1996;27:1453-8.
32. Yamaguchi T, Sano K, Takakura K, Saito I, Shinohara Y, Asano T, et al. Ebselen in acute ischemic stroke: a placebo-controlled, double -blind clinical trial. Stroke 1998;29:12-7.
33. Beaulieu C, Busch E, Rother J, de Crespigny A, Hsia CJ, Moseley ME. Polynitroxyl albumin reduces infarct size in transient focal cerebral ischemia in the rat: potential mechanisms studied by magnetic resonance imaging. J Cereb Blood Flow Metab 1998;18: 1022-31.
34. Zhao Q, Pahlmark K, Smith M-L, Siesjo BK. Delayed treatment with the spin trap alpha-phenyl-N-butyl nitrone (PBN) reduced infarct size following temporary transient middle cerebral artery occlusion in rats. Acta Physiol Scand 1994;152:349-50.
35. Dalkara T, Moskowitz MA. Nitric oxide in cerebrovascular regulation. In: Hsu CY, editor. Ischemic stroke: from basic mechanisms to new drug development. Basel: Karger; 1998. p. 28-47.
36. Maiese K, Tenbroeke M, Kue I. Neuroprotection of lubeluzole is mediated through the signal transduction pathways of nitric oxide. J Neurochem 1997;68:710-14.
37. Diener HC, Hacke W, Hennerici M, Radberg J, Hantson L, De Keyser J. Lubeluzole in acute ischemic stroke. A double-blind, placebo-controlled phase II trial. Lubeluzole International Study Group. Stroke 1996;27:76-81.
38. Grotta J. Lubeluzole treatment of acute ischemic stroke. The US and Canadian Lubeluzole Ischemic Stroke Study Group. Stroke 1997;28:2338-46.
39. Diener HC. Multinational randomised controlled trial of lubeluzole in acute ischaemic stroke. European and Australian Lubeluzole Ischaemic Stroke Study Group. Cerebrovasc Dis 1998;8:172-81.
40. Kuroda S, Nakai A, Kristian T, Siesjo BK. The calmodulin antagonist trifluoperazine in transient focal brain ischemia in rats: anti-ischemic effects and therapeutic window. Stroke 1997;28: 2539-44.
41. Markgraf CG, Velayo NL, Johnson MP, McCarty DR, Medhi S, Koehl JR, et al. Six hour window of opportunity for calpain inhibition in focal cerebral ischemia in rats. Stroke 1998;29:152-8.
42. Hossmann KA. Periinfarct depolarizations. Cerebrovasc Brain Metab Rev 1996;8:195-208.
43. Takano K, Latour LL, Formato JE, Carano RA, Helmer KG, Hasegawa Y, et al. The role of spreading depression in focal ischemia evaluated by diffusion mapping. Ann Neurol 1996;39:308-18.
44. Rother J, deCrespigny AJ, D'Arceuil H, Iwai K, Moseley ME. Recovery of apparent diffusion coefficient after ischemia-inducing spreading depression relates to cerebral perfusion gradient. Stroke 1996;27:980-6.
45. Hossmann K-A. Viability thresholds and the penumbra of focal ischemia. Ann Neurol 1994;36:557-65.
46. Mies G, Kohno K, Hossmann KA. Prevention of peri-infarct DC shift with glutamate antagonist NBQX following occlusion of the middle cerebral artery in rats. J Cereb Blood Flow Metab 1994; 14:802-7.
47. Tatlisumak T, Takano K, Meiler MR, Fisher M. A glycine site antagonist, ZD9379, reduces the number of spreading depressions and infarct size in rats with permanent middle cerebral artery occlusion. Stroke 1998;29:190-5.
48. Green AR, Cross AJ, Snape MF, de Souza RJ. The immediate consequences of MCA occlusion on GABA synthesis in mouse cortex and cerebellum. Neurosci Lett 1992;138:141-4.
49. Snape MF, Baldwin HA, Cross AJ, Green AR. The effects of clomethizole and nimodipine on cortical infarct area after focal cerebral ischemia in the rat. Neuroscience 1993;53:837-44.
50. Wahlgren NG, Clomethiazole acute Stroke Study (CLASS). Efficacy results in a subgroup of 545 patients with total anterior circulation syndrome [abstract]. Stroke 1998;29:287.
51. Bode-Greuel KM, Kirsch J, Horvath E, Glaser T, Traber J. Effects of 5-hydroxytryptamine-receptor agonists on hippocampal damage after transient forebrain ischemia in Mongolian gerbil. Stroke 1990;21(suppl 4):161-4.
52. Garcia JH, Liu KF, Yoshida Y, Lian J, Chen S, del Zoppo GJ. Influx of leukocytes and platelets in an evolving brain infarct (Wistar rat). Am J Pathol 1994;144:188-99.
53. Clark RK, Lee EV, White RF, Jonak ZL, Feuerstein GZ, Barone FC. Reperfusion following focal stroke hastens inflammation and resolution of ischemic injury. Brain Res Bull 1994;35:387-92.
54. Pantoni L, Sarti C, Inzitari D. Cytokines and cell adhesion molecules in cerebral ischemia: experimental basis and therapeutic perspectives. Arterioscler Thromb Vase Biol 1998;18:503-13.
55. Yamasaki Y, Matsuura N, Shozuhara H, Onodera H, Itoyama Y, Kogure K. Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats. Stroke 1995;26:676-81.
56. Loddick SA, Rothwell NJ. Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 1996;16:932-40.
57. Garcia JH, Liu KF, Relton JK. Interleukin-1 receptor antagonist decreases the number of necrotic neurons in rats after middle cerebral artery occlusion. Am J Pathol 1995;147:1477-86.
58. Frenette PS, Wagner DD. Adhesion molecules, Part 1. N Engl J Med 1996;334:1526-9.
59. Zhang RL, Chopp M, Jiang N, Tang WX, Prostak J, Manning AM, et al. Anti-intercellular adhesion molecule-I antibody reduces ischemic cell damage after transient but not permanent middle cerebral artery occlusion in the Wistar rat. Stroke 1995;26: 1438-43.
60. Chen H, Chopp M, Zhang RL, Bodzin G, Chen Q, Rusche JR, et al. Anti-CD11b monoclonal antibody reduces ischemic cell damage after transient focal cerebral ischemia in rat. Ann Neurol 1994; 35:458-63.
61. Sherman DG. The Enlimolab Acute Stroke Trial Investigators. The Enlimolab Acute Stroke Trial: final results [abstract]. Neurology 1997;48:A270.
62. Fisher M, Meadows ME, Do T, Weise J, Trubetskoy V, Charette M, et al. Delayed intravenous administration of basic fibroblast growth factor reduces infarct size following permanent focal cerebral ischemia in rats. J Cereb Blood Flow Metab 1995;15:953-9.
63. Kawamata T, Alexis NE, Dietrich WD, Finklestein SP. Intracisternal basic fibroblast growth factor (bFGF) enhances behavioral recovery following focal cerebral infarction in the rat. J Cereb Blood Flow Metab 1996;16:542-7.
64. The FIBLAST Safety Study Group. Clinical safety trial of intravenous basic fibroblast growth factor (bFGF, FIBLAST) in acute stroke [abstract]. Stroke 1998;29:287.
65. Gross CE, Bednar MM, Howard DB, Sporn MB. Transforming growth factor-beta 1 reduces infarct size after experimental cerebral ischemia in a rabbit model. Stroke 1993;24:558-62.
66. Schabitz WR, Schwab S, Spranger M, Hacke W. Intraventricular brain-derived neurotrophic factor reduces infarct size after focal cerebral ischemia in rats. J Cereb Blood Flow Metab 1997;17: 500-6.
67. Kawamata T, Ren J, Chan TC, Charette M, Finklestein SP. Intracisternal osteogenic protein-1 enhances functional recovery following focal stroke. Neuroreport 1998;9:1441-5.
68. Lopez-Coviella I, Clark WM, Warach SJ, et al. CDP-Choline (citicoline): Potential mechanisms of action and preliminary results in human stroke. In: Goldstein LB, editor. Restorative neurology: advances in pharmacology for recovery after stroke. Armonk (NY): Futura; 1998. p. 195-212.
69. Schabitz WR, Weber J, Takano K, Sandage BW, Locke KW, Fisher M. The effects of prolonged treatment with citicoline in temporary experimental focal ischemia. J Neurol Sci 1996;138: 21-5.
70. Onal MZ, Li F, Tatlisumak T, Locke KW, Sandage BW Jr, Fisher M. Synergistic effects of citicoline and MK-801 in temporary experimental focal ischemia. Stroke 1997;28:1060-5.
71. Clark WM, Warach SJ, Pettigrew LC, Gammans RE, Sabounjian LA. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group. Neurology 1997;49:671-8.
72. Clark WM, Williams BJ, Selzer KA, Zweifler RM, Sabounjian LA for the citicoline acute ischemic stroke study group. Randomized efficacy trial of citicoline in acute ischemic stroke [abstract]. Stroke 1998;29:287.
73. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. JAMA 1998;279:1265-72.
74. Fisher M, Bogousslavsky J. Further evolution for effective therapy for acute ischemic stroke. JAMA 1998;279:1298-303.
75. Zivin JA. Neuroprotective therapies in stroke. Drugs 1997;54(suppl 3):83-9.
76. Waxman SG, Ransom BR, Stys PK. Non-synaptic mechanisms of calcium-mediated injury in CNS white matter. Trends Neurosci 1991;14:461-9.
77. Stys PK. Anoxic and ischemic injury of myelinated axons in CNS white matter: from mechanistic concepts to therapeutics. J Cereb Blood Flow Metab 1998;18:2-25.